MNPR Monopar Therapeutics

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025. EASL is recognized as one of the premier events in the hepatology space and will be held in Amsterdam, Netherlands from May 7 – 10, 2025.

Late-breaker provides an opportunity to present “the most recent and significant findings,” according to EASL. Criteria for late-breaker abstracts include: (1) they present the latest, up-to-date research findings; (2) the research is considered highly significant with the potential to impact the field in a substantial manner; and (3) clinical studies should be prospective. Late-breaker abstracts undergo a rigorous review, and the acceptance rate is lower than regular abstracts with only the most compelling abstracts selected.

Details of the EASL Congress 2025 late-breaker poster presentation are as follows:

Title: Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline

Abstract Number: LB25251

Session: Late-breaker Posters

Date and Time: Wednesday, May 7, 8:30 a.m. CET

Presenter: Karl Heinz Weiss, M.D.

Location: Amsterdam, Netherlands

The poster to be presented at EASL 2025 will be available online at on May 7, 2025.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit:

CONTACT:

Monopar Therapeutics Inc.

Investor Relations

Quan Vu

Chief Financial Officer

Follow Monopar on social media for updates:

X:   LinkedIn:



EN
29/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Monopar Therapeutics

 PRESS RELEASE

Monopar Therapeutics Reports First Quarter 2025 Financial Results and ...

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Assoc...

 PRESS RELEASE

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, one of the most prominent global conferences in liver disease. Monopar’s late-breaker p...

 PRESS RELEASE

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation...

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver (“EASL”) International Liver Congre...

 PRESS RELEASE

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results an...

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summarized recent developments. “2024 was a productive year for Monopar, with the in-licensing of ALXN1840, the initiation of two first-in-human radiopharma Phase 1 clinical trials, and the strengthening of our ...

 PRESS RELEASE

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offe...

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share. In addition to the shares sold in the registered offering,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch